Filament Health CEO Ben Lightburn joined Steve Darling from Proactive to announce the signing of a non-binding term sheet for potential funding of up to US$14.4 million. The funding is in collaboration with an affiliate of Helena Partners Inc., a Cayman-Islands-based advisor and investor.
The infusion of capital is expected to significantly bolster Filament Health's operations, particularly in advancing its drug development programs. Furthermore, this funding will play a crucial role in facilitating the completion of the Proposed Business Combination with the Jupiter Acquisition Corporation. Notably, it is a strategic step towards achieving the company's goal of listing on the Nasdaq stock exchange.
This financial boost demonstrates Filament Health's commitment to driving innovation in the pharmaceutical sector and expanding its presence in the financial markets. Stay tuned for more updates on Filament Health's exciting journey ahead.
Proactive Investors
+1 604-688-8158
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$0.03 |
Daily Volume: | 0 |
Market Cap: | US$7.850M |
November 14, 2024 August 14, 2024 June 03, 2024 May 14, 2024 April 02, 2024 |
Leveraging its vertically-integrated approach from mine to material manufacturing, Graphite One intends to produce high-grade anode material for the lithium-ion electric vehicle battery market and energy storage systems...
CLICK TO LEARN MORESurf Air Mobility is a regional air mobility platform expanding the category of regional air travel to reinvent flying through the power of electrification. In an effort to substantially reduce the cost and environmental impact of...
CLICK TO LEARN MORECOPYRIGHT ©2022 GREEN STOCK NEWS